Isis Pharmaceuticals and Xenon Pharmaceuticals have collaborated to discover and develop antisense drugs as new treatments for the common disease anemia of inflammation (AI).
Subscribe to our email newsletter
Enter your email address so we can get in touch.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.